Skip to Main Content

An experimental immunotherapy developed by Bristol Myers Squibb prevented metastatic melanoma from worsening when added to the company’s approved treatment, Opdivo, the company said Wednesday.

The result is a step forward for immunotherapy, a field that has seen only halting progress since the development of medicines like Opdivo and Merck’s rival treatment, Keytruda.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!